(Q34023772)

30 July 2017

title

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis (English)

1 reference

30 July 2017

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis (English)

1 reference

postmenopausal osteoporosis

6 July 2024

0 references

1 reference

1 reference

Felicia Cosman

1

1 reference

30 July 2017

Erik Fink Eriksen

2

1 reference

30 July 2017

Chris Recknor

3

1 reference

30 July 2017

Núria Guañabens

5

1 reference

30 July 2017

Christian Kasperk

6

1 reference

30 July 2017

Philemon Papanastasiou

7

1 reference

30 July 2017

Aimee Readie

8

1 reference

30 July 2017

Hanumantha Rao

9

1 reference

30 July 2017

Christina Bucci-Rechtweg

11

1 reference

30 July 2017

Steven Boonen

12

1 reference

30 July 2017

Paul D. Miller

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20814967

6 July 2024

Jürg A. Gasser

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20814967

6 July 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20814967

6 July 2024

publication date

1 March 2011

1 reference

full work available at URL

30 July 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fjbmr.238

1 reference

https://academic.oup.com/jbmr/article-pdf/26/3/503/56558947/238_ftp.pdf

6 July 2024

file format

Portable Document Format

1 reference

Journal of Bone and Mineral Research

6 July 2024

published in

1 reference

30 July 2017

volume

26

1 reference

30 July 2017

issue

3

1 reference

30 July 2017

page(s)

503-511

1 reference

Treatment of osteoporosis and prevention of new fractures: role of intravenously administered bisphosphonates

30 July 2017

cites work

1 reference

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

Parathyroid hormone treatment for osteoporosis

21 January 2018

1 reference

Recombinant Human Parathyroid Hormone (1–34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure

21 January 2018

1 reference

Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis

21 January 2018

1 reference

Teriparatide or alendronate in glucocorticoid-induced osteoporosis

21 January 2018

1 reference

Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass

21 January 2018

1 reference

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

21 January 2018

1 reference

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

21 January 2018

1 reference

Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy

21 January 2018

1 reference

Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate

21 January 2018

1 reference

Daily and cyclic parathyroid hormone in women receiving alendronate

21 January 2018

1 reference

Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis

21 January 2018

1 reference

Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate

21 January 2018

1 reference

The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis

21 January 2018

1 reference

Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.

21 January 2018

1 reference

Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study

21 January 2018

1 reference

Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses

21 January 2018

1 reference

Antifracture efficacy of antiresorptive agents are related to changes in bone density.

21 January 2018

1 reference

Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium

21 January 2018

1 reference

A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide

21 January 2018

1 reference

Does early PTH treatment compromise bone strength? The balance between remodeling, porosity, bone mineral, and bone size

21 January 2018

1 reference

Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity

21 January 2018

1 reference

Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women

21 January 2018

1 reference

PTH-analogs: comparable or different?

21 January 2018

1 reference

Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy

21 January 2018

1 reference

Establishing a Reference Interval for Bone Turnover Markers in 637 Healthy, Young, Premenopausal Women From the United Kingdom, France, Belgium, and the United States

21 January 2018

1 reference

Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis

21 January 2018

6

1 reference

Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study

6 July 2024

7

1 reference

Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results from the EUROFORS study

6 July 2024

11

1 reference

Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women

6 July 2024

12

1 reference

Transmission of human herpesvirus 8 by blood transfusion

6 July 2024

15

1 reference

Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis

6 July 2024

16

1 reference

Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal

6 July 2024

17

1 reference

PTH and interactions with bisphosphonates

6 July 2024

25

1 reference

Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells

6 July 2024

27

1 reference

Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women

6 July 2024

37

1 reference

Influence of bone marrow fat on the determination of bone mineral content by QCT

6 July 2024

41

1 reference

Accuracy and the influence of marrow fat on quantitative CT and dual-energy X-ray absorptiometry measurements of the femoral neck in vitro

6 July 2024

42

1 reference

6 July 2024

Identifiers

DOI

10.1002/JBMR.238

1 reference

30 July 2017

1 reference